CRIS Current Research Information System

MARCHETTI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.918
NA - Nord America 1.256
EU - Europa 851
SA - Sud America 187
AF - Africa 123
OC - Oceania 1
Totale 5.336
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.211
SG - Singapore 871
CN - Cina 753
VN - Vietnam 619
IT - Italia 274
HK - Hong Kong 270
KR - Corea 163
BR - Brasile 135
NL - Olanda 126
DE - Germania 78
IN - India 74
SE - Svezia 70
FR - Francia 56
CI - Costa d'Avorio 47
GB - Regno Unito 43
JP - Giappone 39
FI - Finlandia 35
IE - Irlanda 35
SC - Seychelles 34
RU - Federazione Russa 29
CA - Canada 28
ZA - Sudafrica 25
AT - Austria 23
CH - Svizzera 22
PH - Filippine 21
AR - Argentina 19
JO - Giordania 16
PL - Polonia 15
TH - Thailandia 15
BD - Bangladesh 14
BG - Bulgaria 14
ID - Indonesia 14
CL - Cile 12
CO - Colombia 7
IQ - Iraq 7
MX - Messico 7
TW - Taiwan 7
LT - Lituania 6
PK - Pakistan 6
EC - Ecuador 5
ES - Italia 5
JM - Giamaica 5
TR - Turchia 5
UZ - Uzbekistan 4
VE - Venezuela 4
AL - Albania 3
DZ - Algeria 3
PT - Portogallo 3
TG - Togo 3
UA - Ucraina 3
AE - Emirati Arabi Uniti 2
BE - Belgio 2
DO - Repubblica Dominicana 2
IL - Israele 2
KE - Kenya 2
KG - Kirghizistan 2
KZ - Kazakistan 2
ML - Mali 2
MY - Malesia 2
NI - Nicaragua 2
OM - Oman 2
PE - Perù 2
SA - Arabia Saudita 2
UY - Uruguay 2
AU - Australia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BY - Bielorussia 1
CD - Congo 1
CY - Cipro 1
EE - Estonia 1
EG - Egitto 1
GR - Grecia 1
HN - Honduras 1
HR - Croazia 1
IR - Iran 1
KW - Kuwait 1
LB - Libano 1
LV - Lettonia 1
MA - Marocco 1
MK - Macedonia 1
MM - Myanmar 1
MU - Mauritius 1
MZ - Mozambico 1
PY - Paraguay 1
RO - Romania 1
RS - Serbia 1
SN - Senegal 1
TN - Tunisia 1
Totale 5.336
Salva come PNG Salva come JPEG
Città #
Singapore 617
Hefei 281
Hong Kong 249
Ashburn 202
Ho Chi Minh City 164
Seoul 160
San Jose 155
Hanoi 152
Santa Clara 90
Beijing 76
Bologna 69
Los Angeles 61
Boardman 51
Abidjan 47
Chandler 36
Council Bluffs 36
Dublin 34
New York 34
Tokyo 29
Dallas 28
Bengaluru 26
Da Nang 26
Lauterbourg 25
Milan 24
Guangzhou 23
Helsinki 23
Redondo Beach 23
Haiphong 22
Johannesburg 22
Amsterdam 21
Bern 19
São Paulo 18
Castel Maggiore 17
Amman 16
Vienna 16
Nuremberg 14
Shanghai 14
Buffalo 13
Frankfurt am Main 13
Munich 13
Sofia 13
Orem 12
Tongling 12
Turin 12
Warsaw 12
Falkenstein 11
Rome 11
Biên Hòa 10
Chicago 9
Lappeenranta 9
London 9
Atlanta 8
Can Tho 8
Fairfield 8
Montreal 8
Ninh Bình 8
Princeton 8
Rimini 8
Southend 8
Stockholm 8
Boston 7
Hyderabad 7
Hải Dương 7
Nanjing 7
Paris 7
Thái Nguyên 7
Zhengzhou 7
Bari 6
Changsha 6
Chennai 6
Florence 6
Houston 6
Jakarta 6
Manila 6
Moscow 6
Phoenix 6
Toronto 6
Columbus 5
Mexico City 5
Phú Thọ 5
Quezon City 5
Quận Bình Thạnh 5
Redmond 5
San Francisco 5
San Polo di Torrile 5
Seattle 5
Shenzhen 5
Thái Bình 5
Wuhan 5
Xi'an 5
Bangkok 4
Berlin 4
Boydton 4
Brooklyn 4
Bắc Ninh 4
Chengdu 4
Denver 4
Genoa 4
Kingston 4
Mumbai 4
Totale 3.365
Salva come PNG Salva come JPEG
Nome #
Insights into the impact of chromosome 3p mutations in advanced renal cell carcinoma treated with immune-based combinations or targeted therapy: A single-center experience 197
Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis 172
Dual-energy spectral CT in renal cell carcinoma: dawn of a brand-new era? 170
Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma 167
Bone targeting agents in patients with metastatic prostate cancer: State of the art 162
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw 161
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis 161
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study 160
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy 157
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy 153
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study 152
Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives 149
A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience 149
The value of molecular features in predicting efficacy of immuno-combinations in kidney cancer: just a drop in the ocean? 148
State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes 143
Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience 132
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis 129
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review 124
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis 123
18F-Fluorodeoxyglucose Uptake in PDGFRA-Mutant Gastrointestinal Stromal Tumors 123
The Prognostic Role of 68GA-PSMA-PET/CT in Metastatic Hormone-Sensitive Prostate Cancer: A Preliminary Analysis 111
An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma 101
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials 94
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy 91
Immunohistochemical expression of EZH2 in germ cell tumors of the testis: New insights into the genesis and epigenetic reprogramming of these fascinating tumors 91
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma 89
Current androgen receptor antagonists under investigation for resistant prostate cancer: progress and challenges 88
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt 85
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials 83
How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma? 82
Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers 80
Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials 80
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1) 78
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study 75
TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab 74
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma? 72
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis 70
Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer 70
What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it? 69
Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer 67
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study 67
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis 66
Immunohistochemical expression of Nectin-4 and potential implications for enfortumab vedotin therapy in germ cell tumors of the testis: a preliminary study 63
Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma 63
Clinical outcomes and prognostic factors in patients with penile carcinoma: a sub-analysis from Meet-URO 23 (I-RARE) registry study 61
Current androgen receptor antagonists under investigation for resistant prostate cancer 56
Pathological and Clinical Implications of Tumor Microenvironment Evaluated With Multiplex Immunohistochemistry in Testicular Embryonal Carcinoma 53
Prostate cancer and novel pharmacological treatment options - what's new for 2022? 45
Re: First-line Therapy for Advanced Non-Clear Cell Renal Cell Carcinoma. A Systematic Review and Meta-analysis 41
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials 40
Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: A critical overview of recent evidence 38
Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial 38
An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma 37
Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials 36
Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study 35
The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study 30
Totale 5.451
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.188
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.188
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20215 0 0 0 0 0 0 0 0 0 0 0 5
2021/202282 0 0 1 3 2 1 6 20 5 3 29 12
2022/2023341 4 14 7 15 34 32 20 17 90 9 55 44
2023/2024218 19 36 20 14 18 27 6 16 15 12 21 14
2024/20251.409 61 137 96 89 143 58 78 55 34 122 211 325
2025/20263.389 347 445 349 311 347 130 420 111 580 252 97 0
Totale 5.451